Advaxis is actively seeking commercialization partners for the license and development of its proprietary investigational Lm Technology™ immunotherapies.
Advaxis has created more than 20 distinct immunotherapy candidates based on its proprietary platform that are available for partnering in anti-PD-1 combination therapy, recurrent cervical cancer, HPV-associated head and neck cancer, HPV-associated anal cancer, prostate cancer, HER2 expressing tumors, and others.
Interested parties may contact:
Vice President, Business Development
305 College Rd East
Princeton, NJ 0854